Drug Trial Radar · NCT04196491
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
Last checked: Nov 19, 2026Latest source record: Aug 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
May 27, 2020
Primary completion
Jun 7, 2023
Study completion Jun 7, 2023
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Dec 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, phase 1, single arm study intended to determine the optimal target dose and safety of bb2121 in subjects with HR (R-ISS Stage III per IMWG criteria) NDMM. Subjects should have received 3 Cycles of standard induction therapy prior to undergoing leukapheresis procedure to collect autologous mononuclear cells for manufacture of the drug product (bb2121). Following manufacture of the drug product, subjects will receive fourth cycle of induction therapy followed by lymphodepleting therapy with fludarabine and cyclophosphamide prior to bb2121 infusion. Maintenance therapy is recommended for all subjects who have received bb2121 infusion and should be initiated upon adequate bone marrow recovery or from 90-day post-bb2121 infusion, whichever is later.
Conditions
- Multiple Myeloma
Interventions
bb2121Biological
CAR-T Cell Therapy
FludarabineDrug
Lymphodepleting Chemotherapy
CyclophosphamideDrug
Lymphodepleting Chemotherapy
LenalidomideDrug
Maintenance Therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT) ratesTime frame: Up to completion of DLT period after last subject bb2121 infused
- Adverse Events (AEs)Time frame: Approximately 2 years after last subject bb2121 infused
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Local Institution - 119
Phoenix, Arizona
Local Institution - 110
Los Angeles, California
Local Institution - 116
San Francisco, California
Local Institution - 106
Denver, Colorado
Local Institution - 101
Jacksonville, Florida
Local Institution - 113
Tampa, Florida
Local Institution - 108
Atlanta, Georgia
Local Institution - 123
Atlanta, Georgia
Local Institution - 115
Boston, Massachusetts
Local Institution - 122
Boston, Massachusetts
Local Institution - 117
Hackensack, New Jersey
Local Institution - 121
New York, New York
Local Institution - 109
New York, New York
Local Institution - 124
New York, New York
Local Institution - 120
Charlotte, North Carolina
Local Institution - 112
Portland, Oregon
Local Institution - 118
Philadelphia, Pennsylvania
Local Institution - 103
Nashville, Tennessee
Local Institution - 102
Dallas, Texas
Local Institution - 114
Houston, Texas
Local Institution - 104
Seattle, Washington
Local Institution - 107
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.